AU2005216706B2 - NK-1 receptor antagonists anesthesia recovery - Google Patents

NK-1 receptor antagonists anesthesia recovery Download PDF

Info

Publication number
AU2005216706B2
AU2005216706B2 AU2005216706A AU2005216706A AU2005216706B2 AU 2005216706 B2 AU2005216706 B2 AU 2005216706B2 AU 2005216706 A AU2005216706 A AU 2005216706A AU 2005216706 A AU2005216706 A AU 2005216706A AU 2005216706 B2 AU2005216706 B2 AU 2005216706B2
Authority
AU
Australia
Prior art keywords
compound
formula
salt
pharmaceutically acceptable
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005216706A
Other languages
English (en)
Other versions
AU2005216706A1 (en
Inventor
Mary Anne Hickman
Christine Edna Miskell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2005216706A1 publication Critical patent/AU2005216706A1/en
Application granted granted Critical
Publication of AU2005216706B2 publication Critical patent/AU2005216706B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2005216706A 2004-01-30 2005-01-06 NK-1 receptor antagonists anesthesia recovery Ceased AU2005216706B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54069704P 2004-01-30 2004-01-30
US60/540,697 2004-01-30
PCT/IB2005/000010 WO2005082366A1 (en) 2004-01-30 2005-01-06 Nk-1 receptor antagonists anesthesia recovery

Publications (2)

Publication Number Publication Date
AU2005216706A1 AU2005216706A1 (en) 2005-09-09
AU2005216706B2 true AU2005216706B2 (en) 2007-11-29

Family

ID=34910695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005216706A Ceased AU2005216706B2 (en) 2004-01-30 2005-01-06 NK-1 receptor antagonists anesthesia recovery

Country Status (14)

Country Link
US (1) US20070155782A1 (cg-RX-API-DMAC7.html)
EP (1) EP1713479A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007519701A (cg-RX-API-DMAC7.html)
KR (1) KR100880391B1 (cg-RX-API-DMAC7.html)
CN (1) CN1913893A (cg-RX-API-DMAC7.html)
AU (1) AU2005216706B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507325A (cg-RX-API-DMAC7.html)
CA (1) CA2554823A1 (cg-RX-API-DMAC7.html)
IL (1) IL176830A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06007964A (cg-RX-API-DMAC7.html)
NO (1) NO20062965L (cg-RX-API-DMAC7.html)
RU (1) RU2337685C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005082366A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605149B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034099T2 (en) 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника
CN114984223B (zh) * 2022-05-31 2023-06-20 中国人民解放军陆军军医大学第二附属医院 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung
WO2026099213A1 (fr) * 2024-11-05 2026-05-15 Ceva Sante Animale Compositions comprenant du maropitant base et leurs utilisations
FR3168163A1 (fr) * 2024-11-05 2026-05-08 Ceva Sante Animale Compositions aqueuses comprenant du maropitant et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073304A1 (en) * 1999-06-01 2000-12-07 Pfizer Products Inc. Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
WO2003009848A1 (en) * 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US540897A (en) 1895-06-11 Harold f
US540644A (en) 1895-06-11 del yalle
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073304A1 (en) * 1999-06-01 2000-12-07 Pfizer Products Inc. Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
WO2003009848A1 (en) * 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. Gardner et al. Neuropharmacology. Vol. 37, no. 12 1998 *
P. Diemunsch et al. British Journal of Anaesthesia. Vol. 82, no. 2 1999 *

Also Published As

Publication number Publication date
WO2005082366A1 (en) 2005-09-09
BRPI0507325A (pt) 2007-07-03
AU2005216706A1 (en) 2005-09-09
EP1713479A1 (en) 2006-10-25
MXPA06007964A (es) 2007-01-26
WO2005082366A8 (en) 2005-12-15
IL176830A0 (en) 2006-10-31
KR100880391B1 (ko) 2009-01-30
US20070155782A1 (en) 2007-07-05
NO20062965L (no) 2006-07-21
ZA200605149B (en) 2007-11-28
RU2006126828A (ru) 2008-03-10
JP2007519701A (ja) 2007-07-19
RU2337685C2 (ru) 2008-11-10
CA2554823A1 (en) 2005-09-09
KR20060127934A (ko) 2006-12-13
CN1913893A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
JP6929479B2 (ja) 激越の治療のための舌下デクスメデトミジンの使用
CN103998046B (zh) 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
EP2916846B1 (en) Neuroactive steroids and their use to facilitate neuroprotection
JP4745576B2 (ja) 医薬組成物
EP2058010B1 (en) Pharmaceutical composition
CA2176298C (en) A single high dose fluoroquinolone treatment
US20150099783A1 (en) Use of ccr3-inhibitors
JPWO2006134877A1 (ja) 注射剤
HUP0203121A2 (hu) Szubsztituált benzimidazolokat tartalmazó gyógyszerkészítmény és alkalmazása
TWI343819B (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
US20070155782A1 (en) Nk-1 receptor antagonists anesthesia recovery
US10925864B2 (en) Stable liquid injectable solution of midazolam and pentazocine
WO2020128915A1 (en) Oral formulations of branaplam
US8362081B2 (en) Methods for treating hemorrhagic conditions
MXPA06008648A (es) Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion.
US11529357B2 (en) Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
HK1100640A (en) Nk-1 receptor antagonists anesthesia recovery
US20080118555A1 (en) Stable pharmaceutical composition containing desloratadine
EA034152B1 (ru) Антимикробные композиции с шипучими веществами
JP2005522462A (ja) 気道疾患の治療のためのプロトンポンプ阻害剤の使用
Opin Potential disadvantages
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired